Literature DB >> 26126780

Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.

Stephane Heymans1, Arantxa González2,3, Anne Pizard4, Anna P Papageorgiou1, Natalia López-Andrés3,5, Frédéric Jaisser6, Thomas Thum7, Faiez Zannad4, Javier Díez2,3,8.   

Abstract

Myocardial fibrosis is the result of excessive fibrillar collagen synthesis and deposition without reciprocally balanced degradation. It causes cardiac dysfunction, arrhythmias, and ischaemia, and thereby determines the clinical course and outcome of cardiac patients even when adequately treated. Therefore, further research is needed to identify and better understand the factors that trigger and maintain the myocardial fibrotic response against different injuries in a variety of cardiac diseases. Here, we will focus on the following major areas of research: molecules that stimulate the differentiation of fibroblasts into myofibroblasts and subsequently alter collagen turnover (e.g. cardiotrophin-1, galectin-3, NADPH oxidases, and neutrophil gelatinase-associated lipocalin), microRNA-induced alterations of collagen gene expression, and matricellular protein- and lysyl oxidase-mediated alterations of collagen cross-linking and deposition.
© 2015 The Authors. European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Interstitial fibrosis; Therapeutic targets

Mesh:

Substances:

Year:  2015        PMID: 26126780     DOI: 10.1002/ejhf.312

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  34 in total

1.  Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.

Authors:  João Pedro Ferreira; António Barros; Bertram Pitt; Gilles Montalescot; Esteban Lopez de Sa; Christian W Hamm; Marcus Flather; Freek Verheugt; Harry Shi; Adelino Leite-Moreira; John Vincent; Patrick Rossignol; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2018-09-27       Impact factor: 5.460

2.  Based on network pharmacology and in vitro experiments to prove the effective inhibition of myocardial fibrosis by Buyang Huanwu decoction.

Authors:  Tianyue Wang; Xinyu Jiang; Yanmin Ruan; Jun Zhuang; Yuanjun Yin
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 3.  The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation.

Authors:  Z Čarná; P Osmančík
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

4.  Aminoacylase-1 plays a key role in myocardial fibrosis and the therapeutic effects of 20(S)-ginsenoside Rg3 in mouse heart failure.

Authors:  Qiong Lai; Fu-Ming Liu; Wang-Lin Rao; Guang-Ying Yuan; Zhao-Yang Fan; Lu Zhang; Fei Fu; Jun-Ping Kou; Bo-Yang Yu; Fang Li
Journal:  Acta Pharmacol Sin       Date:  2021-12-16       Impact factor: 7.169

5.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

6.  Improving Right Ventricular Function by Increasing BMP Signaling with FK506.

Authors:  Mario Boehm; Xuefei Tian; Md Khadem Ali; Yuqiang Mao; Kenzo Ichimura; Mingming Zhao; Kazuya Kuramoto; Svenja Dannewitz Prosseda; Giovanni Fajardo; Melanie J Dufva; Xulei Qin; Vitaly O Kheyfets; Daniel Bernstein; Sushma Reddy; Ross J Metzger; Roham T Zamanian; Francois Haddad; Edda Spiekerkoetter
Journal:  Am J Respir Cell Mol Biol       Date:  2021-09       Impact factor: 6.914

Review 7.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

8.  Loss of talin in cardiac fibroblasts results in augmented ventricular cardiomyocyte hypertrophy in response to pressure overload.

Authors:  Natalie A Noll; Lance A Riley; Christy S Moore; Lin Zhong; Mathew R Bersi; James D West; Roy Zent; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-25       Impact factor: 5.125

Review 9.  In vitro Assays and Imaging Methods for Drug Discovery for Cardiac Fibrosis.

Authors:  Giorgia Palano; Ariana Foinquinos; Erik Müllers
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

10.  Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis in Dilated Cardiomyopathy.

Authors:  Paweł Rubiś; Ewa Dziewięcka; Magdalena Szymańska; Robert Banyś; Małgorzata Urbańczyk-Zawadzka; Maciej Krupiński; Małgorzata Mielnik; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Piotr Podolec; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Jan Robak; Arman Karapetyan; Ewa Wypasek
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.